Advertisement

Topics

Latest Top Pharmaceutical Companies in South Korea NewsRSS

22:50 EST 20th January 2019 | BioPortfolio

CKD Pharma’s darbepoetin alfa biosimilar launched in Japan

On 4 December 2018, South Korean drugmaker Chong Kun Dang Pharmaceutical (CKD Pharma) announced that it had received approval for its second-generation anaemia biosimilar, CKD‑11101 (darbepoetin alfa).

Korean Health Food Distribution Brand Nature Food Distributes ‘Chong Kun Dang 6-year-old Red Ginseng Gold’ Abroad

Ewha Company said its food brand, Nature Food, will begin an international distribution of health food product, ‘Chong Kun Dang 6-year-old Red Ginseng Gold.’ This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190110005201/en/

NeuroBo Pharmaceuticals to Initiate Phase III Clinical Trial of NB-01 in Adult Patients with Diabetic Neuropathic Pain

Pivotal Phase III study will further evaluate the efficacy of candidate NB-01 on pain associated with diabetic neuropathy NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on novel, disease-modifying therapies for neurodegenerative diseases today announced its plan

Gilead enters deal with Yuhan to develop drugs for advanced fibrosis due to NASH https://www.firstwordpharma.com/node/1616366  $GILD

Gilead enters deal with Yuhan to develop drugs for advanced fibrosis due to NASH https://www.firstwordpharma.com/node/1616366  $GILD

Gilead Inks $785 Million Deal With Yuhan for NASH Development

Gilead Sciences is acquiring the global rights to develop and commercialize novel small molecules against two targets from Yuhan Corporation, based in South Korea. They drugs will be developed to treat advanced fibrosis related to nonalcoholic steatohepatitis (NASH).

$GILD & Yuhan Announce Collab and License Agreement to Develop Novel Investigational Treatments for Advanced Fibrosis Due to #NASH. $15M upfront to Yuhan and up to $770M in milestones #JPM19 https://www.businesswire.com/news/home/20190106005116/en/Gilead-

$GILD & Yuhan Announce Collab and License Agreement to Develop Novel Investigational Treatments for Advanced Fibrosis Due to #NASH. $15M upfront to Yuhan and up to $770M in milestones #JPM19

Gilead Sciences and Yuhan Corporation Announce Collaboration and License Agreement to Develop Novel Investigational Treatments for Advanced Fibrosis Due to Nonalcoholic Steatohepatitis

Gilead Sciences, Inc. (NASDAQ: GILD) and Yuhan Corporation (000100.KS; Yuhan) today announced that the companies have entered into a licensing and collaboration agreement to co-develop novel therapeutic candidates for the treatment of patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH). This press release features multimedia. View the...

Daewoong Pharmaceutical Co Ltd 069620 Financial and Strategic SWOT Analysis Review [Report Updated: 20122018] Prices from USD $125

Daewoong Pharmaceutical Co Ltd 069620 Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies t...

Daewoong Pharmaceutical Co Ltd 069620 Product Pipeline Analysis, 2018 Uate [Report Updated: 19122018] Prices from USD $750

SummaryDaewoong Pharmaceutical Co Ltd Daewoong Pharma is one of the leading manufacturers and distributors of prescription drugs in South Korea. It offers prescription drugs, quasi drugs, medical devices, cosmetics, health foods and APIs. The company produces products in the forms of tablets, capsules, ointments, injections, liquids and sprays. It offers its products for the therapeutic conditions...

Bridge Biotherapeutics Signs US$40M License Agreement with Daewoong Pharmaceutical for Co-development of UC Drug Candidate

SEONGNAM, South Korea, Dec. 19, 2018 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, announced that the company signed a license agreement with Daewoong Pharmaceutical Co., Ltd. for development of BBT-401, the first anti-Pellino-1 compound currently under development for ulcerative colitis (UC) treatment. The company had entere...

Daewoong Pharmaceutical Co Ltd 069620 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 14122018] Prices from USD $250

SummaryDaewoong Pharmaceutical Co Ltd Daewoong Pharma is one of the leading manufacturers and distributors of prescription drugs in South Korea. It offers prescription drugs, quasi drugs, medical devices, cosmetics, health foods and APIs. The company produces products in the forms of tablets, capsules, ointments, injections, liquids and sprays. It offers its products for the therapeutic conditions...

Global and Asia OxygenFree Copper Market Status and Future Forecast 20132023 [Report Updated: 20082018] Prices from USD $3000

SummaryKey Content of Chapters Including and can be customizedPart 1:Market Overview, Development, and Segment by Grade, Product Form, Application RegionPart 2:Global Market by company, Grade, Product Form, Application RegionPart 3:Asia Market by company, Grade, Product Form, Application RegionPart 410:Key Regions of Asia Market by Grade, Product Form, ApplicationPart 11:Company information, Sa...

O’Dang Hummus expands retail presence

O’Dang Hummus announced that Hy-Vee will now be carrying three o

Nanofibers Manufactured for Wearable Power Sources

NewsManufacturing open-mesoporous carbon nanofibers for flexible and wearable power sources.Contributed Author: 

Hanmi Pharmaceuticals Co Ltd 128940 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryHanmi Pharmaceuticals Co Ltd Hanmi Pharma, a subsidiary of Hanmi Science Co Ltd is a developer of prescription drugs and over the counter drugs. The company's prescription drugs include osteoporosis, antibiotics, antidiarrheal, liver supplements and antiemetics. It provides over the counter products such as vitamins, nutritional supplements and calcium supplement, among others. Hanmi Pharma...

World Institute of Kimchi: Function-enhanced kimchi inhibits growth of cancer cells

Proven anticancer effects of Amtak Baechu cabbage, a crossbred of turnip and Baechu cabbage Intake of kimchi made with Amtak Baechu cabbage doubles the rate of pancreatic cancer cell inhibition compared with standard kimchi SEOUL, South Korea, Nov. 16, 2018 /PRNewswire/ -- Worl

Chong Kun Dang Pharmaceutical Corp 185750 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryChong Kun Dang Pharmaceutical Corp CKD Pharma manufactures, distributes, imports and exports prescription drugs, active pharmaceutical ingredients APIs, overthecounter OTC drugs, health supplements and consumer health products. Its product portfolio includes prescription products for the entire segment and therapeutic classes; vitamins; shampoos; hair colors; aerosols; mat vaporizers and mo...

Yuhan Corp 000100 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryYuhan Corp Yuhan researches, develops, manufactures and markets pharmaceutical products. The company offers API's and intermediates for antibiotic, antiviral, antifungal, antiinflammatory, antidiabetic, antiHIV, antiHCV, betalactase inhibitors, PEGlyated compounds and antihistamines. It offers finished goods for the treatment of coronary artery disease, hypertension, hyperlipidemia, cerebra...

PotNetwork Holding's Diamond CBD Presented Chong’s Choice, Showcased at the Las Vegas Convention Center, at the Recent 2018 CBD.io in Collaboration With VAPEXPO Event Held November 9th and 10th

Company Joined the Biggest Names in Vape and Hemp for an Epic Collaboration of Two Swiftly Growing Industries Fort Lauderdale, Fla., Nov. 12, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- PotNetwork Holdings, Inc. (OTC Pink: POTN) (the “Company”) announces that Diamond CBD presented the Chong’s Choice Premium Vape Product Line at VAPEXPO, which based in Paris (France), is one of the wor...

Ildong Pharmaceutical Co Ltd 000230 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12102018] Prices from USD $250

SummaryIldong Pharmaceutical Co Ltd IPC is a manufacturer of pharmaceutical products. The company offers finished drugs, health foods and foods, raw material drugs, cosmetics and medical devices and others. Its raw material drugs comprise synthesis, probiotics, vitamins and biometabolites. IPC also offers finished drugs such as antihistamine drugs, antineoplastic agents, antifungals and antivirals...

Johnson & Johnson Gains Rights to Yuhan's Experimental Lung Cancer Drug Lazertinib

NewsJanssen will assume responsibility for development, manufacturing, and commercialization with exclusive worldwide rights.

J&J's Janssen Inks Deal With Korea’s Yuhan for NSCLC Drug Valued at up to $1.25 Billion

Janssen agreed to pay Yuhan $50 million in upfront money. Yuhan said that Janssen will be responsible for the development of lazertinib. Janssen will also be responsible for manufacturing and commercialization of the drug.

Johnson & Johnson gains rights to Yuhan's experimental lung cancer drug lazertinib https://www.firstwordpharma.com/node/1602121  $JNJ

Johnson & Johnson gains rights to Yuhan's experimental lung cancer drug lazertinib https://www.firstwordpharma.com/node/1602121  $JNJ

Global Iron Casting Market Status and Outlook 20182025 [Report Updated: 02082018] Prices from USD $4000

Report SnapshotKey Content of Chapters Including and can be customized, report is a semifinished version, and it takes 4872 hours to upgradePart 1:Terminology Definition, Industry Chain,Industry Dynamics Regulations and Global Market OverviewPart 2:Upstream Raw Materials / Components Manufacturing Procurement Methods Channels and Cost , Major Regional Production Overview and Trade FlowPart 3:Pr...

Jeil Pharmaceutical Co Ltd 002620 Financial and Strategic SWOT Analysis Review [Report Updated: 08082018] Prices from USD $125

Jeil Pharmaceutical Co Ltd 002620 Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that ...

Advertisement
Quick Search
Advertisement
Advertisement

 

review and buy Top Pharmaceutical Companies in South Korea market research data and corporate reports here